Skip to main content
. 2025 Aug 22;11(34):eadv6937. doi: 10.1126/sciadv.adv6937

Fig. 1. AKR1B10 down-regulated in CRC correlates with poor prognosis.

Fig. 1.

(A) Paired analysis of AKR1B10 mRNA expression in adjacent normal tissues versus primary tumor samples from TCGA colon adenocarcinoma (COAD; n = 41), rectum adenocarcinoma (READ; n = 9), and liver HCC (LIHC; n = 49) database. FPKM, fragments per kilobase of exon model per million mapped fragments. (B) Protein expression of AKR1B10 in COAD tissues compared to paired normal tissues based on cProSite database (n = 96). (C) Quantitative polymerase chain reaction (qPCR) analysis of AKR1B10 mRNA expression in paired CRC (n = 30)/GC (n = 21) tissues and adjacent normal tissues from SYSU-FAH. (D) Western blot analysis of AKR1B10 protein expression in 14 paired adjacent normal tissues (N) and CRC tissues (T) from SYSU-FAH. Rel, relative. (E and F) Representative IHC staining (E) and quantification (F) of AKR1B10 expression in CRC tumor microarrays (TMAs). Scale bars, 50 μm. (G to J) Analysis of AKR1B10 protein expression in CRC TMAs stratified by T stages (G), National Comprehensive Cancer Network stages (H), lymph node metastases (I), and distant metastases (J). n.s., not significant. (K and L) Kaplan-Meier overall survival curves of patients with low versus high AKR1B10 expression, derived from TCGA-COAD (n = 430)/READ (n = 154) databases (K), and IHC analysis of patients with CRC from SYSU-FAH (L) (n = 93). Data are analyzed with unpaired Student’s t test (F and H to J), paired Student’s t test (A to D), and log-rank test (K and L).